Roche Scraps More Alzheimer’s Drug Trials as Data Disappoint
- Shares of partner AC Immune plunge in pre-market trading
- Results are another failure to target early stages of disease
This article is for subscribers only.
Roche Holding AG halted two large studies of an experimental medicine for Alzheimer’s disease after concluding they would fail, adding to a long list of misfires in the effort to find a treatment for the memory-robbing ailment.
Preliminary analysis showed the medicine developed with AC Immune SA, called crenezumab, was unlikely to meet the goal of the studies in patients with an early form of the disease, Roche said in a statement on Wednesday. AC Immune’s shares slumped in pre-market trading in New York, as did those of Biogen Inc., which is developing a rival therapy.